Jaipur : Jaipur: These days the supply of cheap and effective medicine Emijumab for serious patients of hemophilia is stopped from RMACL. This medicine is effective for normal and serious patients. Till now, many types of such factors were being given to the patients which were also very expensive. When the doctors of SMS and JK Lone Hospital treated the patients with this medicine, they got shocking results. It has also been published in International Journal. Due to non-availability of its supply from RMSCL, patients are not able to get this factor. On the other hand, other factors are being purchased by the department which are not as effective for the patients and their price is also very high. Currently, more than 60 patients of hemophilia are coming through SMS every month. In these also, more than 20 patients are new. In the year 2023, Amijumab was used instead of other factors. It gave better results. After this it was published in General. Right now this factor is not available. The biggest advantage is that four weeks Can stop bleeding up to.
Better for normal patients who have developed in-habitat.
In some patients bleeding does not occur spontaneously while in others it starts occurring without any reason. These include factor eight and factor nine. In-habitat develops in many patients. That is, resistance develops towards these factors (medicines) and they do not have any effect. According to General, the risk of developing in-habitat in a patient of hemophilia A is up to 30 percent. The risk of hemophilia B is five percent. In such a situation, till now 7A and FEIBA have been used in patients who have developed in-habitat, but the ineffectiveness of both of them has not been revealed.
The reason is that after the application of 7A factor to the patient, bleeding can be stopped for a maximum of five hours and after the application of FEIBA, bleeding can be stopped for a maximum of 10 hours. While 7A costs up to Rs 2 lakh, FEIBA costs only Rs 1 lakh. But Amiduzumab is a non-factor therapy with the help of which bleeding can be stopped in the patient for four weeks.
Asso of Clinical Hematology of SMS. Professor Dr. Vishnu Sharma says that Amijumab is effective not only for patients who have developed in-habitat but also for normal hemophilia patients. No expert is required to apply it and even nursing staff at the district level can apply it. Amiduzumab is not available in hospitals. According to doctors, some number had come in the year 2023. It was so effective that patients came from Jodhpur, Udaipur, Jhalawar to get it. Now if this is not coming then people don’t even come. The effect of other factors lasts only for five hours. In such a situation, if RMSCL supplies it, not only crores of rupees will be saved but the patients will also be able to get better treatment.
